Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, RWTH Aachen University, Germany.
J Cell Mol Med. 2012 Oct;16(10):2311-20. doi: 10.1111/j.1582-4934.2012.01539.x.
Cell based therapy has been shown to attenuate myocardial dysfunction after myocardial infarction (MI) in different acute and chronic animal models. It has been further shown that stromal-cell derived factor-1α (SDF-1α) facilitates proliferation and migration of endogenous progenitor cells into injured tissue. The aim of the present study was to investigate the role of exogenously applied and endogenously mobilized cells in a regenerative strategy for MI therapy. Lentivirally SDF-1α-infected endothelial progenitor cells (EPCs) were injected after 90 min. of ligation and reperfusion of the left anterior descending artery (LAD) intramyocardial and intracoronary using a new rodent catheter system. Eight weeks after transplantation, echocardiography and isolated heart studies revealed a significant improvement of LV function after intramyocardial application of lentiviral with SDF-1 infected EPCs compared to medium control. Intracoronary application of cells did not lead to significant differences compared to medium injected control hearts. Histology showed a significantly elevated rate of apoptotic cells and augmented proliferation after transplantation of EPCs and EPCs + SDF-1α in infarcted myocardium. In addition, a significant increased density of CD31(+) vessel structures, a lower collagen content and higher numbers of inflammatory cells after transplantation of SDF-1 transgenic cells were detectable. Intramyocardial application of lentiviral-infected EPCs is associated with a significant improvement of myocardial function after infarction, in contrast to an intracoronary application. Histological results revealed a significant augmentation of neovascularization, lower collagen content, higher numbers of inflammatory cells and remarkable alterations of apoptotic/proliferative processes in infarcted areas after cell transplantation.
细胞治疗已被证明可减轻不同急性和慢性动物模型心肌梗死后的心肌功能障碍。进一步表明基质细胞衍生因子-1α(SDF-1α)促进内源性祖细胞增殖和迁移到受损组织中。本研究旨在探讨外源性和内源性动员细胞在心肌梗死后再生治疗策略中的作用。在结扎和再灌注左前降支(LAD)90 分钟后,通过新型啮齿动物导管系统将慢病毒感染的内皮祖细胞(EPC)注射到心肌内和冠状动脉内。移植后 8 周,超声心动图和离体心脏研究显示,与介质对照相比,慢病毒感染 SDF-1 的 EPC 心肌内应用后左心室功能明显改善。与介质注射对照心脏相比,细胞冠状动脉内应用未导致明显差异。组织学显示,在移植 EPC 和 EPC+SDF-1α后,心肌梗死区的凋亡细胞和增殖率明显升高。此外,在移植 SDF-1 转基因细胞后,可检测到 CD31(+)血管结构的密度显著增加,胶原含量降低,炎症细胞增多。与冠状动脉内应用相比,慢病毒感染的 EPC 心肌内应用与梗死后心肌功能的显著改善相关。组织学结果显示,细胞移植后,梗死区的新生血管化、胶原含量降低、炎症细胞增多以及凋亡/增殖过程的显著改变。